Quick Answer
Cue Biopharma, Inc. reported Cash and Equivalents of $27.14 million for fiscal year 2025.
Cue Biopharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $27.14M | +20.8% |
| 2024 | $22.46M | -53.7% |
| 2023 | $48.51M | -6.0% |
| 2022 | $51.61M | -19.8% |
| 2021 | $64.37M | -14.0% |
| 2020 | $74.87M | +69.0% |
| 2019 | $44.29M | +112.9% |
| 2018 | $20.80M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $11.70M | -63.9% | -57.4% |
| June 30, 2025 | $27.49M | -8.4% | +109.3% |
| March 31, 2025 | $13.14M | -68.0% | -41.5% |
| December 31, 2024 | $22.46M | -53.7% | -30.7% |
| September 30, 2024 | $32.42M | -40.7% | +8.0% |
| June 30, 2024 | $30.03M | -43.2% | -26.8% |
| March 31, 2024 | $41.03M | -27.2% | -15.4% |
| December 31, 2023 | $48.51M | -6.0% | -11.3% |
- Cue Biopharma, Inc. showed an increase of +20.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Cue Biopharma, Inc.’s cash and equivalents has grown by 30.5% (from $20.80 million to $27.14 million).
- The most recent figure is from Cue Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: